Subsequent NGS examination identified a mutation in the EZH2 gene with unclear significance and a UBA1 mutation, leading to a diagnosis of very low-risk MDS (IPSS-R of 1) and VEXAS syndrome. This evidence concerns the gene EZH2 and myelodysplastic syndrome.